Otoimmün Epilepsilerin Tedavisi

Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017; 58: 512–521. doi: 10.1111/epi.13709.

. Steriade C, Gillinder L, Rickett K, Hartel G, Higdon L, Britton J, et al.. Discerning the role of autoimmunity and autoantibodies in epilepsy: a review. JAMA Neurol. 2021;78(11): 1383–90.

Dubey D, Alqallaf A, Hays R, Freeman M, Chen K, Ding K, et al.. Neurological autoantibody prevalence in epilepsy of unknown etiology. JAMA Neurol. 2017;74(4): 397–402.

Elisak M, Krysl D, Hanzalova J, Volna K, Bien CG, Leypoldt F, et al.. The prevalence of neural antibodies in temporal lobe epilepsy and the clinical characteristics of seropositive patients. Seizure. 2018;63: 1–6.

Nóbrega-Jr AW, Gregory CP, Schlindwein-Zanini R, Neves FS, Wolf P, Walz R, et al.. Mesial temporal lobe epilepsy with hippocampal sclerosis is infrequently associated with neuronal autoantibodies. Epilepsia. 2018;59(9): e152–6.

de Bruijn M, Bastiaansen AEM, Mojzisova H, van Sonderen A, Thijs RD, Majoie MJM, et al.. Antibodies contributing to focal epilepsy signs and symptoms score. Ann Neurol. 2021;89(4): 698–710

Fisher RS, Boas WVE, Blume W, Elger C, Genton P, Lee P, et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia. 2005; 46: 470–2,

Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014; 55: 475–82.

Beghi E, Carpio A, Forsgren L, Hesdorffer DC, Malmgren K, Sander JW, et al. Recommendation for a definition of acute symptomatic seizure. Epilepsia. 2010; 51: 671–5.

Britton JW. Autoimmune epilepsy. Handb Clin Neurol 2016; 133: 219–245.

Bakpa OD, Reuber M, Irani SR. Antibody-associated epilepsies: clinical features, evidence for immunotherapies and future research questions. Seizure 2016; 41: 26–41.

Jang Y, Kim DW, Yang KI, Byun JI, Seo JG, No YJ, Kang KW, Kim D, Kim KT, Cho YW, Lee ST; Drug Committee of Korean Epilepsy Society. Clinical Approach to Autoimmune Epilepsy. J Clin Neurol. 2020 Oct;16(4): 519–529.

Titulaer MJ, Soffietti R, Dalmau J, et al. Screening for tumours in paraneoplastic syndromes: report of an EFNS Task Force. European Journal of Neurology. 2011; 18(1): 19–23. doi: 10.1111/j.1468-1331.2010.03120.x

Abboud H, Probasco J, Irani SR, Ances B, Benavides DR, Bradshaw M, Christo PP, Dale RC, Fernandez-Fournier M, Flanagan EP, Gadoth A, George P, Grebenciucova E, Jammoul A, Lee ST, Li Y, Matiello M, Morse AM, Rae-Grant A, Rojas G, Rossman I, Schmitt S, Venkatesan A, Vernino S, Pittock SJ, Titulaer M; Autoimmune Encephalitis Alliance Clinicians Network. Autoimmune encephalitis: proposed recommendations for symptomatic and long-term management. J Neurol Neurosurg Psychiatry. 2021 Mar 1;92(8): 897–907.

Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. The Lancet Neurology. 2013; 12(2): 157–165. doi: 10.1016/S1474-4422(12)70310-1

Dalmau J, Rosenfeld MR. Autoimmune encephalitis update. Neuro Oncol 2014; 16: 771–8. 10.1093/neuonc/nou030

Gadoth A, Pittock SJ, Dubey D, et al. Expanded phenotypes and outcomes among 256 LGI1/CASPR2-IgG-positive patients. Ann Neurol 2017;82: 79–92. 10.1002/ana.24979 [

Feyissa AM, Lamb C, Pittock SJ, et al. Antiepileptic drug therapy in autoimmune epilepsy associated with antibodies targeting the leucine-rich glioma-inactivated protein 1. Epilepsia Open 2018;3: 348–56. 10.1002/epi4.12226

de Bruijn MAAM, van Sonderen A, van Coevorden-Hameete MH, et al. Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABAb>Bb>R encephalitis. Neurology 2019;92: e2185–96. 10.1212/WNL.0000000000007475

Feyissa AM, López Chiriboga AS, Britton JW. Antiepileptic drug therapy in patients with autoimmune epilepsy. Neurol Neuroimmunol Neuroinflamm. 2017 May 10;4(4): e353

Bianchi M, Rossoni G, Sacerdote P, Panerai AE, Berti F. Carbamazepine exerts anti-inflammatory effects in the rat. Eur J Pharmacol 1995; 294: 71–74

Himmerich H, Bartsch S, Hamer H, et al. Modulation of cytokine production by drugs with antiepileptic or mood stabilizer properties in anti-CD3- and anti-Cd40-stimulated blood in vitro. Oxid Med Cell Longev 2014; 2014: 806162

Beghi E, Shorvon S. Antiepileptic drugs and the immune system. Epilepsia 2011;52(suppl 3): 40–44.

Jubiz W, Meikle AW, Levinson RA, Mizutani S, West CD, Tyler FH. Effect of diphenylhydantoin on the metabolism of dexamethasone. N Engl J Med. 1970;283(1): 11–4.

Nation RL, Evans AM, Milne RW. Pharmacokinetic drug interactions with phenytoin (Part II). Clin Pharmacokinet. 1990;18(2): 131–50.

Wen X, Wang JS, Kivistö KT, Neuvonen PJ, Backman JT. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9). Br J Clin Pharmacol. 2001;52(5): 547–53

Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol. 2003;2(6): 347–56. 125.

PJ. Use of corticosteroids in neuro-oncology. Anticancer Drugs. 1995;6(1): 19–33. 126.

Audet-Walsh E, Auclair-Vincent S, Anderson A. Glucocorticoids and phenobarbital induce murine CYP2B genes by independent mechanisms. Expert Opin Drug Metab Toxicol. 2009;5(12): 1501–1

Schmitt C, Kuhn B, Zhang X, Kivitz AJ, Grange S. Disease drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis. Clin Pharmacol Ther. 2011;89(5): 735–40.

de Bruijn MAAM, van Sonderen A, van Coevorden-Hameete MH, Bastiaansen AEM, Schreurs MWJ, Rouhl RPW, et al.. Evaluation of seizure treatment in anti-LGI1, anti-NMDAR, and anti-GABABR encephalitis. Neurology. 2019;92(19): e2185–96.

Zeng W, Cao L, Zheng J, Yu L. Clinical characteristics and long-term prognosis of relapsing anti-N-methyl-D-aspartate receptor encephalitis: A retrospective, multicenter, self-controlled study. Neurol Sci. (2021) 42: 199–207. doi: 10.1007/s10072–020-04482–7.

Huang Q, Ma M, Wei X, Liao Y, Qi H, Wu Y, et al. Characteristics of seizure and antiepileptic drug utilization in outpatients with autoimmune encephalitis. Front Neurol. (2019) 9: 1136. doi: 10.3389/fneur.2018.01136

Liu X, Yan B, Wang R, Li C, Chen C, Zhou D, et al. Seizure outcomes in patients with anti-NMDAR encephalitis: A follow-up study. Epilepsia. (2017) 58: 2104–11. doi: 10.1111/epi.13929

Du J, Guo Y, Zhu Q. Use of anti-seizure medications in different types of autoimmune encephalitis: A narrative review. Front Neurol. 2023 Mar 23; 14: 1111384. doi: 10.3389/fneur.2023.1111384. PMID: 37034075; PMCID: PMC10076804.

Zhong R, Zhang X, Chen Q, Li M, Guo X, Lin W. Acute symptomatic seizures and risk of epilepsy in autoimmune encephalitis: A retrospective cohort study. Front Immunol. (2022) 13: 813174. doi: 10.3389/fimmu.2022.813174.

Zhang J, Sun J, Zheng P, Feng S, Yi X, Ren H, et al. Clinical characteristics and follow-up of seizures in children with anti-NMDAR encephalitis. Front Neurol. (2022) 12: 801289. doi: 10.3389/fneur.2021.801289

López-Chiriboga AS, Flanagan EP. Diagnostic and therapeutic approach to autoimmune neurologic disorders. Semin Neurol 2018; 38: 392–402.

Kumar N, Abboud H. Iatrogenic CNS demyelination in the era of modern biologics. Mult Scler 2019; 25: 1079–85.

Heine J, Prüss H, Bartsch T, et al. Imaging of autoimmune encephalitis--Relevance for clinical practice and hippocampal function. Neuroscience 2015; 309: 68–83.

Bhatia S, Schmitt SE. Treating Immune-Related Epilepsy. Curr Neurol Neurosci Rep. 2018 Feb 14;18(3): 10. doi: 10.1007/s11910–018-0821-y. PMID: 29445957.

Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 2016; 15: 391–404. 10.1016/S1474–4422(15)00401–9

Titulaer MJ, Höftberger R, Iizuka T, et al. Overlapping demyelinating syndromes and anti-N-methyl-D-aspartate receptor encephalitis. Ann Neurol 2014; 75: 411–28.

Fang B, McKeon A, Hinson SR, et al. Autoimmune glial fibrillary acidic protein Astrocytopathy: a novel meningoencephalomyelitis. JAMA Neurol 2016; 73: 1297–307.

Irani SR, Michell AW, Lang B, et al. Faciobrachial dystonic seizures precede LGI1 antibody limbic encephalitis. Ann Neurol 2011; 69: 892–900. 10.1002/ana.22307

Sechi E, Flanagan EP. Antibody-mediated autoimmune diseases of the CNS: challenges and approaches to diagnosis and management. Front Neurol. 2021;12: 673339.

DeSena AD, Noland DK, Matevosyan K, et al. Intravenous methylprednisolone versus therapeutic plasma exchange for treatment of anti-N-methyl-D-aspartate receptor antibody encephalitis: a retrospective review. J Clin Apher 2015;30: 212–6. 10.1002/jca.21363

Flammer J, Neziraj T, Rüegg S, Pröbstel AK. Immune Mechanisms in Epileptogenesis: Update on Diagnosis and Treatment of Autoimmune Epilepsy Syndromes. Drugs. 2023 Feb;83(2): 135–158.

McKeon A, Pittock SJ. Rituximab: Principles of use and adverse effects in neurologic disorders. In: UpToDate [İnternet]. Waltham (MA): Wolters Kluwer Health; 2025. Erişim tarihi: 26 Ekim 2025. Erişim adresi: https://www.uptodate.com/contents/rituximab-principles-of-use-and-adverse-effects-in-neurologic-disorders

Multipl Skleroz Çalışma Grubu Tanı ve Tedavi Rehberi . Editörler: Efendi H, Yandım Kuşçu D. 2018.

Scheibe F, Prüss H, Mengel AM, et al. Bortezomib for treatment of therapy-refractory anti-NMDA receptor encephalitis. Neurology 2017;88: 366–70.

Lee W-J, Lee S-T, Moon J, et al. Tocilizumab in autoimmune encephalitis refractory to rituximab: an institutional cohort study. Neurotherapeutics 2016;13: 824–32.

Lim J-A, Lee S-T, Moon J, et al. New feasible treatment for refractory autoimmune encephalitis: low-dose interleukin-2. J Neuroimmunol 2016;299: 107–11.

54.Nosadini M, Mohammad SS, Ramanathan S, et al. Immune therapy in autoimmune encephalitis: a systematic review. Expert Review of Neurotherapeutics. 2015; 15(12): 1391–1419. doi: 10.1586/14737175.2015.1115720

Shin YW, Lee ST, Park KI, et al. Treatment strategies for autoimmune encephalitis. Therapeutic Advances in Neurological Disorders. 2018; 11: 1756285617722347. doi: 10.1177/1756285617722347

López-Chiriboga A.S., Flanagan E.P. Diagnostic and therapeutic approach to autoimmune neurologic disorders. Seminars in Neurology. 2018; 38(4): 392–402. doi: 10.1055/s-0038-1660819

Zuliani L, Nosadini M, Gastaldi M, Spatola M, Iorio R, Zoccarato M, et al. Management of antibody-mediated autoimmune encephalitis in adults and children: literature review and consensus-based practical recommendations. Neurol Sci. 2019;40(10): 2017–2030.

Epilepsi Çalışma Grubu Tanı ve Tedavi Rehberi 2015. Editörler: Yeni SN, Gürses. C. 2015 .

Almeida V, Pimentel J, Campos A, Bentes C, Maruta C, Morgado C, Martins IP. Surgical control of limbic encephalitis associated with LGI1 antibodies. Epileptic Disord. 2012; 14: 345–348.

Kerling F, Blumcke I, Stefan H. Pitfalls in diagnosing limbic encephalitis-a case report. Acta Neurol Scand. 2008; 118: 339–342.

Malter MP, Frisch C, Zeitler H, Surges R, Urbach H, Helmstaedter C, Elger CE, Bien CG. Treatment of immune-mediated temporal lobe epilepsy with GAD antibodies. Seizure. 2015; 30: 57–63

Muehlebner A, Groeppel G, Pahs G, Hainfellner JA, Prayer D, Czech T, Feucht M. Beneficial effect of epilepsy surgery in a case of childhood non-paraneoplastic limbic encephalitis. Epilepsy Res. 2010; 90: 295–299.

Carreño M, Bien CG, Asadi-Pooya AA, Sperling M, Marusic P, Elisak M, Pimentel J, Wehner T, Mohanraj R, Uranga J, Gómez-Ibáñez A, Villanueva V, Gil F, Donaire A, Bargalló N, Rumià J, Roldán P, Setoain X, Pintor L, Boget T, Bailles E, Falip M, Aparicio J, Dalmau J, Graus F. Epilepsy surgery in drug resistant temporal lobe epilepsy associated with neuronal antibodies. Epilepsy Res. 2017 Jan;129: 101–105.

Li Y, Tymchuk S, Barry J, Muppidi S, Le S. Antibody Prevalence in Epilepsy before Surgery (APES) in drug-resistant focal epilepsy. Epilepsia. 2021 Mar;62(3): 720–728.

Ramanathan S, Bleasel A, Parratt J, et al. Characterisation of a syndrome of autoimmune adult onset focal epilepsy and encephalitis. J Clin Neurosci 2014; 21: 1169–1175.

Quek AM, Britton JW, McKeon A, et al. Autoimmune epilepsy: clinical characteristics and response to immunotherapy. Arch Neurol 2012; 69: 582–593.

Chan E, Mani AR. Assessing the therapeutic potential of vagus nerve stimulation in autoimmune diseases: A systematic review. Physiol Rep. 2025 Feb;13(3): e70230.

Pavlov, V. A. , & Tracey, K. J. (2017). Neural regulation of immunity: Molecular mechanisms and clinical translation. Nature Neuroscience, 20(2), 156–166. 10.1038/nn.4477.

Tracey, K. (2009). Reflex control of immunity. Nature Reviews Immunology, 9, 418–428.

Jin, H. , Li, M. , Jeong, E. , Castro‐Martinez, F. , & Zuker, C. S. (2024). A body‐brain circuit that regulates body inflammatory responses. Nature, 630, 695–703. 10.1038/s41586–024-07469-y

Howland, R. H. (2014). Vagus nerve stimulation. Current Behavioral Neuroscience Reports, 1(2), 64–73. 10.1007/s40473–014-0010–5

Shao, P. , Li, H. , Jiang, J. , Guan, Y. , Chen, X. , & Wang, Y. (2023). Role of Vagus nerve stimulation in the treatment of chronic pain. Neuroimmunomodulation, 30(1), 167–183. 10.1159/000531626.

Camarena-Rubio KJ, Flores-Patiño B, Macías López JU, Pichardo-Rojas D, Bravo Osorno VI, Gomez-Oropeza I, Castelo-Pablos MF, Mejía-Pérez SI, Paredes E, Del Río-Quiñones MA, Hernandez Vanegas L. Immediate Postoperative Activation of Vagus Nerve Stimulation (VNS) for Super-refractory Status Epilepticus: A Case Report. Cureus. 2024 Dec 28;16(12): e76509.

Mehboob S, Sureshkumar SM, Fernandes L, Wright E, Ray M, Goodden J, Maguire M. Refractory status epilepticus arrested by vagus nerve stimulation. Pract Neurol. 2024 Mar 19;24(2): 129–133. doi: 10.1136/pn-2023–003896. PMID: 3787534.Formun Üstü

Kurukumbi M, Leiphart J, Asif A, Wang J. Vagus Nerve Stimulation (VNS) in Super Refractory New Onset Refractory Status Epilepticus (NORSE). Case Rep Neurol Med. 2019 Jan 21;2019: 7852017

Feyissa AM, Mirro EA, Wabulya A, Tatum WO, Wilmer-Fierro KE, Won Shin H. Brain-responsive neurostimulation treatment in patients with GAD65 antibody-associated autoimmune mesial temporal lobe epilepsy. Epilepsia Open. 2020 Apr 14;5(2): 307–313.

Chen B, Lundstrom BN, Crepeau AZ, Dacpano L, Lopez-Chiriboga AS, Tatum WO, Freund B, Feyissa AM. Brain responsive neurostimulation device safety and effectiveness in patients with drug-resistant autoimmune-associated epilepsy. Epilepsy Res. 2022 Aug;184: 106974.

Li Q, Shan Y, Wei P, Zhao G. The comparison of DBS and RNS for adult drug-resistant epilepsy: a systematic review and meta-analysis. Front Hum Neurosci. 2024 Jun 19;18: 1429223.

Sivathanu D, Kewalramani D, Kumar Manokaran R. Favorable response to classic ketogenic diet in a child with anti-GAD 65 antibody mediated super refractory status epilepticus. Epilepsy Behav Rep. 2022 Jun 7;19: 100557.

Tayutivutikul N, Wanleenuwat P, Panapongvasin T, Klajing R, Iwanowski P. Dietary effects on antiseizure drug metabolism and management of epilepsy. Seizure. 2022 Nov;102: 14–21.

Klein P, Tyrlikova I, Mathews GC. Dietary treatment in adults with refractory epilepsy: a review. Neurology. 2014 Nov 18;83(21): 1978–85.